mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2012-746mrj-431Research ArticleСтатьиArticlesПрименение цитрата уралит-У у больных подагрой и нефролитиазомExperience with Uralyt-U citralite used in patients with gout and nephrolithiasisEliseyevMaksim SergeyevichEliseyevMaksim Sergeyevichelimax@rambler.ruДенисовИ. С.DenisovI S-БарсковаВ. Г.BarskovaV G-20120809201263№3 (2012)4952Copyright © Eliseyev M.S., Денисов И.С., Барскова В.Г., 20122012Eliseyev M.S., Денисов И.С., Барскова В.Г.Eliseyev M.S., Denisov I.S., Barskova V.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/431

В статье приведены результаты открытого исследования применения цитрата уралит-У у 30 больных подагрой и нефролитиазом. Показано, что, помимо быстрой оптимизации рН мочи, применение препарата приводит к снижению сывороточного уровня мочевой кислоты, коррелирующего с увеличением ее экскреции. Прием препарата отличается хорошей приверженностью лечению, не влияет на показатели функции почек.

The paper gives the results of an open-label trial of the Uralyt-U citrate used in 30 patients with gout and nephrolithiasis. In addition to rapid urine pH optimization, the use of the drug is shown to cause a reduction in the serum level of uric acid, correlating with its enhanced excretion. The use of the agent features good compliance and fails to affect renal functional parameters.

подаграмочевая кислотанефролитиазцитратыУралит-Уgouturic acidnephrolithiasiscitratesUralyt-UReferences<div><p>Soucie J.M., Coates R.J., McClellan W. et al. Relation between geographic variability in kidney stones prevalence and risk factors for stones. Am J Epid 1996; 143: 487-95.</p><p>Pearle M.S, Calhoun E., Curhan G.C. Urolithiasis. In: Litwin M.S., Saigal C.S. (eds). Urologic Diseases in America. Washington, DC: NIDDK, 2007; 283—319.</p><p>Wallace K.L., Riedel A.A., Joseph-Ridge N. et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in amanaged care population. J Rheum 2004; 31: 1582—7.</p><p>Favus M.J. Chapter 14. Nephrolithiasis. In Diseases of bone and calcium metabolism. 2010 http://www.endotext.org/parathyroid/ parathyroidcontributors.htm.</p><p>Ngo T.C., Assimos D.G. Uric acid nephrolithiasis: recent progress and future directions. Rev Urol 2007; 9(1): 17—27.</p><p>Coe J.H.F.L. Evidence for durable kidney stone prevention over several dacades. BJU Int 2009; 5; 103(9): 1238—46.</p><p>Saito J., Matsuzawa Y., Ito H. et al. The alkalizer citrate reduces serum uric Acid levels and improves renal function in hyperuricemic patients treated with the xanthine oxidase inhibitor allopurinol. Endocr Res 2010; 35(4): 145—54.</p><p>Елисеев М.С., Денисов И.С., Барскова В.Г. Клинический опыт применения препарата Уралит-У у больных подагрой и нефролитиазом. Совр. ревматол. 2012; 1: 44-8.</p><p>Riedel A.A., Nelson M., Joseph-Ridge N. et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheum 2004; 31: 1575-81.</p><p>Zhang W., Doherty M., Bardin T. et al. Clinical Studies Including Therapeutics (ESCISIT) EULAR Standing Committee For International Part II: Management. Report of a task force of the EULAR evidence based recommendations for gout. Ann Rheum Dis 2006; 65: 1312-24.</p><p>Khanniazi M.K., Khanam A., Naqvi S.A. et al. Study of potassium citrate treatment of crystalluric nephrolithiasis. Biomed Pharmacother 1993; 47(1): 25-8.</p></div><br /><div><p>Soucie J.M., Coates R.J., McClellan W. et al. Relation between geographic variability in kidney stones prevalence and risk factors for stones. Am J Epid 1996; 143: 487-95.</p><p>Pearle M.S, Calhoun E., Curhan G.C. Urolithiasis. In: Litwin M.S., Saigal C.S. (eds). Urologic Diseases in America. Washington, DC: NIDDK, 2007; 283—319.</p><p>Wallace K.L., Riedel A.A., Joseph-Ridge N. et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in amanaged care population. J Rheum 2004; 31: 1582—7.</p><p>Favus M.J. Chapter 14. Nephrolithiasis. In Diseases of bone and calcium metabolism. 2010 http://www.endotext.org/parathyroid/ parathyroidcontributors.htm.</p><p>Ngo T.C., Assimos D.G. Uric acid nephrolithiasis: recent progress and future directions. Rev Urol 2007; 9(1): 17—27.</p><p>Coe J.H.F.L. Evidence for durable kidney stone prevention over several dacades. BJU Int 2009; 5; 103(9): 1238—46.</p><p>Saito J., Matsuzawa Y., Ito H. et al. The alkalizer citrate reduces serum uric Acid levels and improves renal function in hyperuricemic patients treated with the xanthine oxidase inhibitor allopurinol. Endocr Res 2010; 35(4): 145—54.</p><p>Елисеев М.С., Денисов И.С., Барскова В.Г. Клинический опыт применения препарата Уралит-У у больных подагрой и нефролитиазом. Совр. ревматол. 2012; 1: 44-8.</p><p>Riedel A.A., Nelson M., Joseph-Ridge N. et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheum 2004; 31: 1575-81.</p><p>Zhang W., Doherty M., Bardin T. et al. Clinical Studies Including Therapeutics (ESCISIT) EULAR Standing Committee For International Part II: Management. Report of a task force of the EULAR evidence based recommendations for gout. Ann Rheum Dis 2006; 65: 1312-24.</p><p>Khanniazi M.K., Khanam A., Naqvi S.A. et al. Study of potassium citrate treatment of crystalluric nephrolithiasis. Biomed Pharmacother 1993; 47(1): 25-8.</p></div><br />

The authors declare that there are no conflicts of interest present.